JP2018523703A - 抗炎症性ペプチドおよびその使用 - Google Patents

抗炎症性ペプチドおよびその使用 Download PDF

Info

Publication number
JP2018523703A
JP2018523703A JP2018521713A JP2018521713A JP2018523703A JP 2018523703 A JP2018523703 A JP 2018523703A JP 2018521713 A JP2018521713 A JP 2018521713A JP 2018521713 A JP2018521713 A JP 2018521713A JP 2018523703 A JP2018523703 A JP 2018523703A
Authority
JP
Japan
Prior art keywords
seq
peptide
fragment
biologically active
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523703A5 (https=
Inventor
カルディ ノラ
カルディ ノラ
ロペス シリル
ロペス シリル
アドレフィオ アレッサンドロ
アドレフィオ アレッサンドロ
Original Assignee
ニューリタス リミテッド
ニューリタス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15177013.8A external-priority patent/EP3118215A1/en
Priority claimed from EP15177017.9A external-priority patent/EP3118216A1/en
Application filed by ニューリタス リミテッド, ニューリタス リミテッド filed Critical ニューリタス リミテッド
Publication of JP2018523703A publication Critical patent/JP2018523703A/ja
Publication of JP2018523703A5 publication Critical patent/JP2018523703A5/ja
Priority to JP2021173218A priority Critical patent/JP7288026B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
JP2018521713A 2015-07-16 2016-07-18 抗炎症性ペプチドおよびその使用 Pending JP2018523703A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021173218A JP7288026B2 (ja) 2015-07-16 2021-10-22 抗炎症性ペプチドおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15177013.8 2015-07-16
EP15177013.8A EP3118215A1 (en) 2015-07-16 2015-07-16 Anti-inflammatory peptides, and uses thereof
EP15177017.9A EP3118216A1 (en) 2015-07-16 2015-07-16 Cellular growth and proliferation promoting peptides, and uses thereof
EP15177017.9 2015-07-16
PCT/EP2016/067090 WO2017009484A1 (en) 2015-07-16 2016-07-18 Anti-inflammatory peptides, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021173218A Division JP7288026B2 (ja) 2015-07-16 2021-10-22 抗炎症性ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2018523703A true JP2018523703A (ja) 2018-08-23
JP2018523703A5 JP2018523703A5 (https=) 2019-08-22

Family

ID=56686757

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018521713A Pending JP2018523703A (ja) 2015-07-16 2016-07-18 抗炎症性ペプチドおよびその使用
JP2021173218A Active JP7288026B2 (ja) 2015-07-16 2021-10-22 抗炎症性ペプチドおよびその使用
JP2023086030A Active JP7739355B2 (ja) 2015-07-16 2023-05-25 抗炎症性ペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021173218A Active JP7288026B2 (ja) 2015-07-16 2021-10-22 抗炎症性ペプチドおよびその使用
JP2023086030A Active JP7739355B2 (ja) 2015-07-16 2023-05-25 抗炎症性ペプチドおよびその使用

Country Status (12)

Country Link
US (4) US10463591B2 (https=)
EP (3) EP3954700A1 (https=)
JP (3) JP2018523703A (https=)
KR (3) KR20230132623A (https=)
CN (2) CN114835784B (https=)
AU (2) AU2016293129B2 (https=)
BR (1) BR112018000660A2 (https=)
CA (1) CA2992378A1 (https=)
DK (1) DK3322430T3 (https=)
ES (1) ES2806989T3 (https=)
MX (2) MX377692B (https=)
WO (1) WO2017009484A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102548A (ko) * 2020-02-11 2021-08-20 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932498T3 (es) * 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
JP7340314B2 (ja) * 2020-01-15 2023-09-07 Tdk株式会社 米に含まれるタンパク質の含有量を測定する方法
FR3114744B1 (fr) 2020-10-02 2024-01-05 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer le confort de la peau et/ou des muqueuses et/ou l’apparence des phanères
EP4265630A4 (en) * 2020-12-16 2024-12-11 Ajou University Industry-Academic Cooperation Foundation ANTI-INFLAMMATORY PEPTIDE TO PREVENT OR TREAT ATOPIC DERMATITIS
CN114478702B (zh) * 2022-04-06 2023-12-12 中南林业科技大学 一种米糠来源短肽及其在治疗皮肤损伤中的应用
CN116375828B (zh) * 2022-09-08 2024-06-04 浙江大学 一种具有抗菌活性的抗菌肽kta及其应用
CN116253782B (zh) * 2022-09-08 2024-06-04 浙江大学 一种广谱抗菌肽ktr及其应用
CN116589528A (zh) * 2022-09-21 2023-08-15 江阴天江药业有限公司 一种广地龙特征肽及其应用
FR3141066B1 (fr) * 2022-10-24 2026-04-10 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer la matrice extracellulaire du derme de la peau et/ou des muqueuses
CN116491631B (zh) * 2023-05-26 2024-06-25 青岛农业大学 一种预制菜红烧肉及其制备方法
WO2024259556A1 (en) * 2023-06-19 2024-12-26 Viage Therapeutics, Inc. Uses of therapeutic peptides
CN117736271B (zh) * 2023-06-29 2024-08-09 长沙理工大学 一种米渣蛋白源免疫活性肽及其应用
WO2025133189A1 (en) * 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
EP4666996A1 (en) * 2024-06-21 2025-12-24 Quiris Healthcare GmbH & Co. KG Composition containing peptides of vegetable origin
CN120574921B (zh) * 2025-08-06 2026-02-06 浙江诺衍生物科技有限公司 一种有助于降血糖的大米肽及其应用
CN120590476A (zh) * 2025-08-06 2025-09-05 浙江诺衍生物科技有限公司 一种有助于降血糖的七肽及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5520935A (en) 1991-03-07 1996-05-28 Novo Nordisk A/S Method for production of pea protein hydrolyzate
US5516642A (en) 1992-11-16 1996-05-14 Bristol-Myers Squibb Company Polypeptides derived from major histocompatibility complex Class I antigen
JP2673659B2 (ja) 1994-02-11 1997-11-05 株式会社ホーネンコーポレーション ペプチド
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
IT1313572B1 (it) 1999-07-27 2002-09-09 Enichem Spa Procedimento per la preparazione di epossidi.
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP2001335596A (ja) 2000-05-24 2001-12-04 Kenji Sakamoto 新規ペプチド及びその医薬用途
AR035860A1 (es) 2001-04-17 2004-07-21 Femtolink Biotechnologies Llc Metodos de deteccion por espectrometria de masa y cuantificacion de proteinas blanco especificas en muestras biologicas complejas
AU2003290582A1 (en) 2002-11-04 2004-06-07 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
WO2005023290A2 (en) 2003-05-23 2005-03-17 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
JP4256389B2 (ja) 2003-11-17 2009-04-22 セダーマ テトラペプチドとトリペプチドの混合物を含む組成物
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US8575307B2 (en) 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
KR100759495B1 (ko) 2006-02-17 2007-09-18 재단법인서울대학교산학협력재단 친수성 생리활성 펩타이드와 소수성 물질을 포함한자기조립 나노구조체
US8343531B2 (en) 2006-04-21 2013-01-01 Meiji Co., Ltd. Composition containing peptide as active ingredient
US9034402B2 (en) 2007-04-16 2015-05-19 Solae, Llc Protein hydrolysate compositions having improved sensory characteristics and physical properties
US20110214199A1 (en) 2007-06-06 2011-09-01 Monsanto Technology Llc Genes and uses for plant enhancement
CA2697413A1 (en) * 2007-08-24 2009-03-05 Mylexa Pty Limited Modulators of hypersensitivity reactions
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
WO2011007612A1 (ja) * 2009-07-13 2011-01-20 不二製油株式会社 経口性抗炎症剤及び経口性抗炎症ペプチド
WO2011122937A1 (en) 2010-03-29 2011-10-06 N.V. Nutricia Pea protein peptides with anti helicobacter pylori activity
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
WO2013092851A1 (en) * 2011-12-21 2013-06-27 Laboratorios Ordesa, S.L. Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
CN105163748B (zh) * 2013-02-19 2017-11-21 达能股份公司 用于肥胖症的功能性多肽
CN105708748B (zh) 2014-12-04 2020-06-30 玫琳凯有限公司 化妆品组合物
US20170183386A1 (en) 2015-07-16 2017-06-29 Nuritas Limited Peptides, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEPTIDES, vol. 32, no. 1, JPN6020025322, January 2011 (2011-01-01), pages 125 - 130, ISSN: 0004306553 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102548A (ko) * 2020-02-11 2021-08-20 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도
KR102354916B1 (ko) 2020-02-11 2022-01-26 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도

Also Published As

Publication number Publication date
DK3322430T3 (da) 2020-06-29
EP3747425A1 (en) 2020-12-09
EP3322430A1 (en) 2018-05-23
EP3954700A1 (en) 2022-02-16
CN114835784B (zh) 2025-06-13
US10463591B2 (en) 2019-11-05
JP7739355B2 (ja) 2025-09-16
KR20180029237A (ko) 2018-03-20
AU2016293129B2 (en) 2021-01-28
JP7288026B2 (ja) 2023-06-06
US11779531B2 (en) 2023-10-10
US20190029939A1 (en) 2019-01-31
CN114835784A (zh) 2022-08-02
CN108348568B (zh) 2021-12-28
AU2016293129A1 (en) 2018-02-01
KR20230132623A (ko) 2023-09-15
MX377692B (es) 2025-03-10
ES2806989T3 (es) 2021-02-19
CA2992378A1 (en) 2017-01-19
EP3322430B1 (en) 2020-03-25
CN108348568A (zh) 2018-07-31
US20240238184A1 (en) 2024-07-18
AU2021202423A1 (en) 2021-05-13
KR102576571B1 (ko) 2023-09-11
MX2018000697A (es) 2018-08-15
US20220233425A1 (en) 2022-07-28
KR102307260B1 (ko) 2021-10-01
JP2022009415A (ja) 2022-01-14
US20200060956A1 (en) 2020-02-27
JP2023109950A (ja) 2023-08-08
KR20210120134A (ko) 2021-10-06
BR112018000660A2 (pt) 2019-05-14
WO2017009484A1 (en) 2017-01-19
MX2020010806A (es) 2020-10-28
US11253456B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
JP7739355B2 (ja) 抗炎症性ペプチドおよびその使用
JP2023126479A (ja) グルコースの促進性輸送における使用のためのペプチド
US20230355704A1 (en) Growth promoting peptides, and uses thereof
HK40069687A (en) Anti-inflammatory peptides derived from rice proteins (oryza sativa) and uses thereof
BR122025009933A2 (pt) Método não terapêutico para retardar ou inibir o envelhecimento da pele humana, método e uso não terapêuticos para tratar ou cuidar de sinais visíveis de envelhecimento e curativo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210622